Deutsche Bank Remains a Buy on Sanofi (SNYNF)
In a report released today, Emmanuel Papadakis from Deutsche Bank maintained a Buy rating on Sanofi, with a price target of €105.00.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Papadakis covers the Healthcare sector, focusing on stocks such as Novo Nordisk, GlaxoSmithKline, and Sanofi. According to TipRanks, Papadakis has an average return of 4.4% and a 54.04% success rate on recommended stocks.
In addition to Deutsche Bank , Sanofi also received a Buy from Bank of America Securities’s Sachin Jain in a report issued on January 23. However, on the same day, Kepler Capital maintained a Hold rating on Sanofi (Other OTC: SNYNF).
SNYNF market cap is currently €96.75B and has a P/E ratio of 10.74.
Read More on SNYNF:
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.